Skip to main content
. Author manuscript; available in PMC: 2023 Jul 1.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2022 Dec 19;116(3):533–543. doi: 10.1016/j.ijrobp.2022.12.015

Table 3.

Treatment-relatedlateadverseeventrates

RT + cisplatin RT + cisplatin + cetuximab P value
Any late (>90 d from start of RT) (n = 432) (n = 416)
Grade 3–4 any adverse event 57.4% 61.3% .26
Grade 3–4 dysphagia 39.6% 38.2%
Grade 3–4 radiation mucositis 5.3% 7.0%
Grade 3–4 mucositis/stomatitis (clinical examination): pharynx 4.9% 6.0%
Grade 3–4 hearing impaired 6.0% 5.0%
Grade 3–4 weight decreased 7.6% 8.7%
Grade 3–4 osteonecrosis 6.0% 4.8%
Grade 2–3 dry mouth 47.0% 45.9%